Hello. My name is Ying Yuan.
I'm a professor in Biostatistics
at MD Anderson Cancer Center.
Today I'm going to talk about
how to design early phase drug combination trial.
So here is outline of the talk.
First, I will talk about the challenges
for designing drug combination trials
then I will talk about some specific designs
for drug combination trial,
specifically, I will talk about
how to design a trial to find a single MTD,
and how to design a trial
to find its MTD contour.
Then I will introduce some software
to implement those designs,
and I will finish the talk
with a summary statement.
As we know, the primary objective
of phase I trial
is to find its maximum tolerated dose,
which is defined as a dose
with a specific targeted toxicity rate
So for single-agent trials,
the standard assumption is that
toxicity monotonically increases with the dose.
So in this case, we only find a dose
with a specific target toxicity rate.